File(s) under permanent embargo

Reason: Under embargo until April 2022. After this date a copy can be supplied under Section 51(2) of the Australian Copyright Act 1968 by submitting a document delivery request through your library, or by emailing

The development of 53BP1 inhibitors using REFiL– an efficient workflow for early stage hit to lead optimisation in FBDD

posted on 26.04.2021, 00:27 by BEATRICE CHIEW
Breast cancer is a commonly diagnosed form of cancer. A person is 6-times more likely to develop breast cancer if they have inherited mutations to the BRCA-1 gene. One potential means of preventing this is by inhibiting a protein called 53BP1. This work details the synthesis and testing of over 1000 potential drug-like compounds against 53BP1. It also demonstrates one of the first applications of a novel workflow hoped to expedite drug discovery called REFiL – the Rapid Elaboration of Fragments into Leads. In under 3 years, 7 promising leads were identified against this potential new anti-cancer target.


Campus location


Principal supervisor

Martin Scanlon

Additional supervisor 1

Bradley Croy Doak

Year of Award


Department, School or Centre

Medicinal Chemistry


Doctor of Philosophy

Degree Type